[Explosive growth of uterine leiomyomas and carcinologic ovarian risk in a non-menopausal patient with BRCA1-BRCA2 mutation treated by tamoxifen].
OBJECTIVE
To report the case of significant growth of a myoma in a premenopausal woman with a suspicion of BRCA1 and BRCA2 mutation, treated by tamoxifen for a hormonodependent breast cancer and to point out the carcinologic ovarian risks with a mutation BRCA1-BRCA2 in this context. Case. Four months after surgical treatment, chemotherapy and the beginning of tamoxifen, an explosive growth of the abdomen justified pelvic echography and laparoscopy confirming the diagnosis of uterine myoma. A polymyomectomy by laparotomy was performed.


CONCLUSIONS
Use of tamoxifen in premenopausal woman with subjacent gynecological pathologies, whether BRCA1-BRCA2 mutation is present or not can prove to be delicate. A regular clinical and echographic monitoring is necessary.
Doridot
V
V
Service de Chirurgie Générale et Sénologique, Institut Curie, 26, rue d'Ulm, 75005 Paris, France.
This
P
P
Clough
K B
KB
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002273:Carcinogens / Q000009:adverse effects*; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics; D003131:Combined Modality Therapy; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D006801:Humans; D007044:Hysterectomy; D010535:Laparoscopy; D007889:Leiomyoma / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery; D008408:Mastectomy; D009154:Mutation / Q000235:genetics*; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics*; D017697:Premenopause / Q000187:drug effects*; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000175:diagnosis / Q000209:etiology* / Q000601:surgery
D018931:Antineoplastic Agents, Hormonal; D002273:Carcinogens; D013629:Tamoxifen